Duke University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Duke University sits in the top decile of US sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count).
Duke University: 1,725 sponsored US clinical trials, 187 recruiting.
Duke University sponsors 1,725 registered US clinical trials on ClinicalTrials.gov, 187 of them currently recruiting, and 1,244 completed. 175 of these trials are in Phase 3-4 (later-stage) and 311 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 15 trials.
Top-decile sponsor footprint
Duke University ranks in the top decile of sponsors by registered trial count (#9 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,244 of 1,444 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,725 total, page 4 of 35
Ferritin and Iron Burden in SAH sIRB
NCT03754725
GSD VI and GSD IX Natural History
NCT04454216
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
ADRC Clinical Cohort (Alzheimer's Disease)
NCT06703541
A Study of Facilitators and Barriers to Improve Acute Kidney Injury in Children Through Mobile Health Intervention
NCT04403633
Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study
NCT06595251
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
NCT04278404
Duke APOL1 Research Biorepository
NCT04160507
A Prospective Registry of Pediatric Cellular Therapy Patients at Risk for Endothelial Dysfunction, Sinusoidal Obstruction Syndrome and/or Multi-Organ Dysfunction Syndrome (MODS).
NCT05090345
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
NCT04085029
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
NCT03511118
Intraoperative OCT Guidance of Intraocular Surgery II
NCT03713268
A Phase 2 Study of Home Care Following Autologous Hematopoietic Stem Cell Transplantation
NCT03667599
Abdominal Wall Transplant
NCT03310905
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
NCT03276923
Abductor Reattachment Methods in Proximal Femur Replacements: What is the Best Method?
NCT03261544
Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
NCT03144206
Retinal Imaging in Neurodegenerative Disease
NCT03233646
A Long-term Follow-up Study of Gaucher Disease
NCT03190837
Machine Learning for Handheld Vascular Studies
NCT02932176
Cognitive and Neurological Pathologies in Pompe Disease
NCT04639336
Community Park-Based Programs for Health Promotion: Active Older Adults Prospective Cohort Study
NCT06604650
Pilot Study for Speculum Free Cervical Cancer Screening
NCT04107181
Stool Transplants to Treat Refractory Clostridium Difficile Colitis
NCT02127398
Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study
NCT06596265
GBE Deficiency (GSD IV and APBD) Natural History Study
NCT02683512
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Natural History Study of Patients With Hypophosphatasia (HPP)
NCT02237625
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
NCT01915511
Pharmacokinetics of Drugs Administered to Children
NCT03481881
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
NCT01665326
Duke Lupus Registry
NCT00512694
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome
NCT00482794
Cervical Cancer Detection Using Optical Spectroscopy
NCT00900575
Drug-Induced Liver Injury (DILI) Network Retrospective
NCT00360646
DILIN - Prospective Study
NCT00345930
Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
NCT01745237
Dine and DASH Into Wellness Pilot Study
NCT07175896
Adaptation and Pilot Testing of a Mindfulness-Based Insomnia and Symptom Management Intervention for Women With Breast Cancer Receiving Treatment in Rural Medically Underserved Areas
NCT06529120
Pancoronavirus Vaccine Study in Healthy Adults
NCT06950177
ACHIEVE Pilot Statins for Vascular Protection
NCT06551701
VictORION-INCLUSION: Evaluating Inclisiran for Cholesterol Managment in Heart Disease
NCT06249165
Designing a Virtual Reality Intervention to Improve Physical and Psychological Health in Intensive Care Units
NCT06797895
The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB
NCT05818254
Evaluation Of A Virtual Cardiology Program To Improve Outcomes After Acute Decompensated Heart Failure
NCT06592508
RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)
NCT06404099
RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)
NCT06404112
RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)
NCT06404060
Eye Plaque Brachytherapy for Ocular Melanoma
NCT06432660
You & Me Healthy: Youth Empowered Self-Care Substudy (YES)
NCT06255093
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 136 |
| Phase 2 | 175 |
| Phase 3 | 41 |
| Phase 4 | 134 |
Therapeutic Areas
What is open in the Duke University pipeline
187 recruiting of 1,725 indexed (11% open); 1,244 completed (72%).
Phase mix: 175 late (III/IV) vs 311 early (I/II) (early-phase heavy).
Top condition: Obesity (15 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Duke University: open-pipeline peers nationwide
Peers matched on 1,725 registered trials and 11% open enrollment, not the therapeutic-area sidebar.
Duke University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,725 trials (± recruiting share)
- University of California, San Francisco · 1,713 trials · 16% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 11% open enrollment (± trial volume)
- Carnegie Mellon University · 11% recruiting · 37 trials
- CAMC Health System · 11% recruiting · 28 trials
- UConn Health · 11% recruiting · 178 trials
- Hartford Hospital · 11% recruiting · 75 trials
Related
What to do with this Duke University page
1,725 registered trials is a research-attention snapshot, not an endorsement of Duke University or any single study.
- 187 of Duke University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Duke University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Duke University pipeline card: 1,725 registered trials from official public datasets.Report a data error.